Floatz logo

Fosbretabulin

Neoplasms, Ovarian

The Christie NHS Foundation TrustPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neoplasms, Ovarian cohort.

Asset / SponsorPhaseRating
gw786034
The Christie NHS Foundation Trust
Phase 2BB
Dfn-15
Roswell Park Cancer Institute
Phase 2B
Inno-206
Janssen Research & Development, LLC
Phase 1B
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE
Bristol-Myers Squibb
Phase 2B
Recombinant Human Interleukin-18
GlaxoSmithKline
Phase 1CC
Polyiclc
CanariaBio Inc.
Phase 1CC

Same molecule, other indications

Fosbretabulin is also rated in:

neoplasmDormant
B
Indicative ·
57 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
cancer of unknown primary siteDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →